Serene Non-Invasive Prenatal Screening

• Trisomies of chromosomes 21, 18, and 13, corresponding to Down, Edwards, and Patau syndromes, respectively.
• Aneuploidies of all chromosomes (presence/absence of an extra chromosome), including the sex chromosomes (XY).
• Microdeletion/microduplication syndromes (loss/gain of a small portion of a chromosome), with a resolution >7MB.

Valid for singleton pregnancies:

• Singleton
• Twin pregnancies 2
• In vitro fertilization or egg donation

¹ Consult your doctor.
² It is not possible to assess the risk for sex chromosome aneuploidies; however, if the Y chromosome is detected, the test does not allow for determining the sex of each fetus individually.
³ In the event of the loss of one of the fetuses (vanishing twin), the pregnancy will be treated, with regard to fetal DNA, as a twin pregnancy.

• Using next-generation mass sequencing (NGS).
• Risk and fetal fraction calculations are performed using a dual algorithm, increasing the accuracy of the analysis:

Published data: Mark D. Pertile et al., Clinical Chemistry, Volume 67, Issue 9, September 2021

With the best prenatal diagnostic platform

The Serene test provides accurate results even in samples with low fetal fractions using CE-IVDR-marked software.

Quality Assurance:

The Serene test complies with the recommendations of leading scientific societies and specialty boards in medical genetics and obstetrics/gynecology:

• Directorate-General for Health (DGS);
• American College of Obstetricians and Gynecologists (ACOG);
• Society for Maternal-Fetal Medicine (SMFM);
• International Society for Prenatal Diagnosis (ISPD);

Serene is an innovative, state-of-the-art prenatal screening test.
Results should always be interpreted in the context of all clinical information, and a high-risk result should be confirmed through an invasive diagnostic test.